Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) added $8.66 (25%) to $42.65 on Monday after reporting that its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,